Stocks · News reference
Canaccord Genuity Maintains Hold on Zimmer Biomet Holdings, Raises Price Target to $100
Canaccord Genuity analyst Caitlin Roberts maintains Zimmer Biomet Holdings (NYSE:ZBH) with a Hold and raises the price target from $83 to $100.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — ZIMMER BIOMET HOLDINGS, INC. (ZBH)
Filed: 2026-09-08 AccNo: 0001193125-26-385256 Size: 230 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Shares of medical device-related companies are trading lower amid possible sympathy with Boston Scientific after that company announced it was likely to miss its FY26 and Q3 adjusted EPS and net sales growth guidance following a previously announced cybersecurity incident that affected operations.